Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4101174 in Advanced or Metastatic Solid Tumors
NCT06238479Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 7
01
Overview
Phase 1, open-label trial of ETx-22 in solid tumor, urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and 7 more (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Recommended Phase 2 Dose at 28 days and Overall Response Rate at 48 months. Started Mar 2024; status: active, not recruiting.
02
Drugs
ETx-22
03
Conditions
solid tumorurothelial carcinoma (UC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on NCT06238479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238479.